Drug Profile
Research programme: Eph-targeting peptides - AstraZeneca/Burnham Institute
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator The Burnham Institute
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 08 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)